Yes. It is EMA-approved (since 2013) and US FDA-approved (2015) for diabetes mellitus, among other markets.

How does it differ from a traditional premix insulin?

Unlike biphasic premixes, its basal component is ultra-long-acting degludec, and BOOST trials generally showed lower nocturnal hypoglycaemia than biphasic insulin aspart 30.

What are the main risks?

Hypoglycaemia, which can be severe or fatal, plus weight gain and injection-site reactions; because it delivers both fast and ultra-long insulin, dosing must be tied to meals.

In trials it was injected subcutaneously once or twice daily with main meals and titrated to targets, but actual dosing must be individualised by a clinician.

EMA-approvedaka Ryzodeg

Insulin degludec/aspart — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Insulin degludec/aspart (also known as Ryzodeg) is a peptide catalogued under Hormones & Metabolic (Insulin combination). It is described as: Insulin receptor agonist. Documented context: Diabetes mellitus. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Insulin degludec/aspart?

Insulin degludec/insulin aspart (IDegAsp, brand Ryzodeg 70/30) is a soluble co-formulation combining 70% ultra-long-acting insulin degludec for basal coverage with 30% rapid-acting insulin aspart for mealtime coverage in a single injection.

It is approved for diabetes mellitus in the European Union (EMA, since 2013) and by the US FDA (2015), among other markets.

Evidence level is high: efficacy and safety derive from the phase 3 BOOST randomised controlled trial programme in type 1 and type 2 diabetes, supported by mechanistic and real-world studies.

How does Insulin degludec/aspart work?

The two components act independently in one solution: degludec forms soluble multi-hexamers after injection that release monomers slowly for a flat, ultra-long basal profile, while aspart is absorbed rapidly to blunt post-meal glucose rises.

Both components lower glucose by activating the insulin receptor to increase glucose uptake and suppress hepatic glucose production.

What does the research say about Insulin degludec/aspart?

In uncontrolled, insulin-treated type 2 diabetes, twice-daily IDegAsp achieved HbA1c control non-inferior to biphasic insulin aspart 30 while reducing confirmed and nocturnal hypoglycaemia. ^[1]
The proof-of-concept trial confirmed a single formulation can deliver ultra-long basal coverage from degludec plus a rapid mealtime boost from aspart, versus glargine, in insulin-naive type 2 diabetes. ^[2]
In Asian patients inadequately controlled on prior insulin, IDegAsp reached HbA1c comparable to biphasic insulin aspart 30 with lower nocturnal hypoglycaemia. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial — Fulcher GR et al., Diabetes Care 2014. (Phase 3a RCT (BOOST))
[2] A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial — Heise T et al., Diabetes Care 2011. (Proof-of-concept RCT)
[3] Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial — Kaneko S et al., Diabetes Research and Clinical Practice 2015. (Phase 3 RCT)
[4] Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST: SIMPLE USE) — Park SW et al., Diabetic Medicine 2017. (RCT (BOOST: SIMPLE USE))
[5] Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials — Fulcher G et al., Diabetes Therapy 2019. (Post hoc analysis of BOOST RCTs)
[6] Initiating or switching to insulin degludec/insulin aspart in a real-world population with type 2 diabetes — Fulcher GR et al., Internal Medicine Journal 2024. (Real-world observational study)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Reported trial regimens administered IDegAsp subcutaneously once or twice daily with main meals, titrated to fasting glucose targets.

Actual dosing is individualised and set by a prescribing clinician; this entry provides research context only, not instructions.

Side effects & safety profile

Hypoglycaemia is the principal risk and can be severe or fatal; because the co-formulation delivers both a fast and an ultra-long insulin, mistimed dosing relative to meals can drive glucose too low.

Across BOOST trials IDegAsp generally showed lower nocturnal hypoglycaemia than biphasic insulin aspart 30, but overall hypoglycaemia risk remains and requires glucose monitoring.

Weight gain and injection-site reactions can occur, and this product is not interchangeable unit-for-unit with other insulins or premixes.

Stacking & combinations

IDegAsp is typically used as a self-contained basal-plus-bolus injection and may be combined with oral glucose-lowering agents under clinician supervision rather than layered with separate basal insulin.

Finding Insulin degludec/aspart vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is a single-injection co-formulation (Ryzodeg 70/30) combining 70% ultra-long-acting degludec for basal coverage and 30% rapid-acting aspart for mealtime coverage.

References

[1] Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial — Fulcher GR et al., Diabetes Care 2014. PMID: 24812432. View sourceStudy: Phase 3a RCT (BOOST)Twice-daily IDegAsp matched biphasic insulin aspart 30 on HbA1c with less confirmed and nocturnal hypoglycaemia.
[2] A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial — Heise T et al., Diabetes Care 2011. PMID: 21285389. View sourceStudy: Proof-of-concept RCTThe degludec-plus-aspart co-formulation provided effective glucose control versus glargine, establishing the concept.
[3] Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial — Kaneko S et al., Diabetes Research and Clinical Practice 2015. PMID: 25498130. View sourceStudy: Phase 3 RCTIDegAsp achieved comparable HbA1c to biphasic insulin aspart 30 with lower nocturnal hypoglycaemia in Asian patients.
[4] Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST: SIMPLE USE) — Park SW et al., Diabetic Medicine 2017. PMID: 26773557. View sourceStudy: RCT (BOOST: SIMPLE USE)Once-daily IDegAsp was effectively titrated using either a simple or stepwise algorithm.
[5] Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials — Fulcher G et al., Diabetes Therapy 2019. PMID: 30474818. View sourceStudy: Post hoc analysis of BOOST RCTsIn elderly patients, IDegAsp gave similar glycaemic control to biphasic insulin aspart 30 with less hypoglycaemia.
[6] Initiating or switching to insulin degludec/insulin aspart in a real-world population with type 2 diabetes — Fulcher GR et al., Internal Medicine Journal 2024. PMID: 39171857. View sourceStudy: Real-world observational studyReal-world initiation of or switching to IDegAsp was associated with improved glycaemic control.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.